Summary
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype and shows large variation in outcome. Hodgkin lymphoma (HL) is less common and highly curable, but treatment may cause significant long-term side effects.
This thesis aimed to identify new prognostic markers that may aid treatment stratification for improvement of survival with least possible side effects.
In DLBCL, peripheral blood protein analysis identified a cluster of patients with particularly poor outcome. The highly inflammatory protein signature of these patients was associated with expansion of monocytic myeloid-derived suppressor cells and activation of T cells. The Systemic Protein Deviation (SPD) score was developed to allow identification of these patients through assessment of only four proteins, and this was validated in a separate patient cohort.
The peripheral blood protein profile of HL patients differed from that of DLBCL. In HL, the combination of high levels of two proteins, placental growth factor (PGF) and TNF-related weak inducer of apoptosis (TWEAK), was associated with progression-free survival.
More info about the public defence
Ask will give a Trial lecture the same day at 10:15 on the given topic: "Artificial intelligence tools for precision cancer diagnostics and treatment selection".